在宫癌治疗后的现实结果:来自大学的结果
Rachel L Furuya1, Katelin Boak2, Mary M Mullen3
1Department of Obstetrics and Gynecology, Washington University School of Medicine, MSC 8064-37-1005, 660 S. Euclid Ave, St. Louis, MO 63110, USA.
Gynecologic oncology reports
|August 20, 2025
概括
在治疗晚期子宫癌方面, pembrolizumab 显示出有效性,平均整体存活期为 47. 5 个月. 患者的表现状态是影响实际结果的关键因素.
科学领域:
- 癌症学
- 免疫疗法
- 宫癌研究
背景情况:
- 宫癌仍然是一个重大的全球健康挑战,特别是在晚期或复发阶段.
- 一种免疫检查点抑制剂Pembrolizumab已经成为一个有前途的治疗选择.
研究的目的:
- 评估使用博利祖马布治疗的宫癌患者的实际生存结果.
- 确定与预后不佳相关的危险因素.
- 评估pembrolizumab在该群体中的安全性和毒性.
主要方法:
- 在44名接受布罗利祖马布治疗的晚期或复发性宫癌患者中进行了回顾性研究.
- 卡普兰 - 梅尔方法用于估计整体存活率 (OS) 和无进展存活率 (PFS).
- 考克斯的比例危险模型来评估患者特征与OS之间的关联.
主要成果:
- 平均生存期为47. 5个月,平均PFS为9. 1个月.
- 在23%的患者中观察到完全反应.
- 东部合作性瘤组绩效状态 (PS) > 1 的患者死亡风险增加了6倍 (p=0. 0038).
- 7% 的不良反应是3级或更高的.
结论:
- 在现实环境中, pembrolizumab 在晚期/复发性子宫癌中显示出安全性和有效性.
- 性能状况是治疗建议的关键因素,因为不良的PS可能会限制生存效益.
- 需要进行进一步的研究,以探索患者在良好表现状态下实现完全反应的治愈潜力.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
